Tumori最新文献

{"title":"Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia.","authors":"Yan Cheng, Hongwei Wu","doi":"10.1177/03008916251346563","DOIUrl":"10.1177/03008916251346563","url":null,"abstract":"<p><strong>Objective: </strong>Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in approximately 6-10% of acute myeloid leukemia (AML) patients. Ivosidenib (IVO) is a small-molecule inhibitor of mutant IDH1. This study delves into the mechanism of IVO with hypomethylating agents (HMAs) (azacitidine or decitabine) for treating IDH1-mutated AML through the PI3K/AKT pathway.</p><p><strong>Methods: </strong>IDH1^R132H-mutated MOLM-13 (IDH1^R132H-MOLM-13) cells were constructed. The effects of the drugs, both individually and in combination, on IDH1^R132H-MOLM-13 cell proliferation and apoptosis were assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide and flow cytometry, with combination index (CI) values calculated using CompuSyn software. <i>IDH1</i>, <i>DNMT1</i>, <i>PI3K</i> and <i>AKT</i> gene mRNA levels, and the PI3K/AKT pathway- and histone lysine methylation-related protein levels in IDH1^R132H-MOLM-13 cells were determined by RT-qPCR and Western blot.</p><p><strong>Results: </strong>IDH1^R132H-mutated MOLM-13 cells (IDH1^R132H-MOLM-13) were successfully constructed. The IDH1 inhibitor, either as a monotherapy or combined with HMAs, effectively inhibited IDH1^R132H-MOLM-13 cell proliferation, and the combination therapy exhibited synergistic effects (CI < 1). The combination therapy increased cell proportion in the G2/M phase and apoptotic rate. Both treatment modalities reduced <i>IDH1</i>, <i>DNMT1</i>, <i>PI3K</i> and <i>AKT</i> mRNA levels and histone lysine methylation levels (H3K4me3, H3K9me3, H3K27me3); besides, PI3K and AKT phosphorylation levels were reduced, with the reductions being more significant in cells undergoing combination therapy. The indexes did not differ significantly between cells undergoing the two modalities of combined treatments.</p><p><strong>Conclusion: </strong>The IDH1 inhibitor with HMAs suppressed IDH1^R132H-MOLM-13 cell proliferation and viability and decreased the methylation level by repressing the phosphorylation of the PI3K/AKT pathway, showing a synergistic inhibitory effect.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251346563"},"PeriodicalIF":2.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement.","authors":"Zachary S Feuer, Richard S Matulewicz, Ramsankar Basak, Donna A Culton, Kimberly Weaver, Kristalyn Gallagher, Hung-Jui Tan, Tracy L Rose, Matthew Milowsky, Marc A Bjurlin","doi":"10.1177/03008916251347175","DOIUrl":"https://doi.org/10.1177/03008916251347175","url":null,"abstract":"<p><strong>Purpose: </strong>Most patients with cancer do not participate in a clinical trial. Understanding clinical participation rates, and the barriers and motivators that influence participation may help identify opportunities for improvement in accrual.</p><p><strong>Methods: </strong>A cross-sectional analysis of cancer survivors was conducted using the Health Information National Trends Survey (HINTS) administered in 2020. Primary outcome was clinical trial participation amongst patients with cancer. Secondary outcomes were motivators and barriers to influence clinical trial participation. Logistic regression was employed to assess the association of clinical trials being discussed as a cancer treatment option with social determinants.</p><p><strong>Results: </strong>Six hundred and eighteen respondents (weighted population estimate 22,723,047) with a self-reported history of cancer were included. Overall, 15.7% reported an invitation to participate in a clinical trial, of which 37.8% participated. Clinical trials were discussed as a cancer treatment option amongst 13.5% of respondents. Knowledge of clinical trials was low (9.3%). Reported motivators included trying new care (72.3%), wanting to get better (88.9%), getting paid (40.1%), helping other people (73.0%), and encouragement from the doctor (73.7%) or family/friends (59.5%). Reported barriers included getting transportation, childcare or paid time off work (42.4%), and standard care not covered by insurance (69.6%). Race (Other, OR 3.84) and income (<$35k, OR 5.84) were associated with discussion of clinical trials as a cancer treatment option.</p><p><strong>Conclusion: </strong>Clinical trial treatment discussion, invitation, and participation are low among patients with a history of cancer. Although the study identified multiple motivators and barriers to participation, improvement in the rates of discussion and invitation to participate in a clinical trial are required. Nevertheless, addressing the identified barriers and motivators that influence clinical trial participation may be a strategy to optimize patient enrollment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251347175"},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?","authors":"Fausto Petrelli, Antonio Ghidini, Italo Sarno, Alessandro Iaculli, Angeli Irene, Giovanna Moleri, Mauro Rossitto, Lorenzo Dottorini","doi":"10.1177/03008916251328539","DOIUrl":"https://doi.org/10.1177/03008916251328539","url":null,"abstract":"<p><strong>Introduction: </strong>The strategic addition of immune checkpoint inhibitors (ICIs) to chemotherapy (CT) offers a potential paradigm shift in the treatment of elderly cancer patients. This systematic review evaluates the impact of ICIs combined with CT on the overall survival (OS) of patients aged 65 and older.</p><p><strong>Material and methods: </strong>Using the terms \"immune checkpoint inhibitors\" and (PD-1 or PD-L1 or CTLA-4) and (\"cancer\" or \"carcinoma\") and (\"elderly\" or \"older\" or \"65 years\" or \"70 years\"), we searched PubMed, Embase, and the Cochrane Library through March 2024. We selected only English language, phase II-III randomized controlled trials comparing first-line CT + ICIs vs. CT alone for metastatic cancers, with subgroups reporting outcomes of elderly patients (according to the authors' cutoff of at least 65 years). Hazard ratios (HR) for OS with relative 95% confidence intervals (95%CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studiesResults:The study synthesizes data from 46 phase III randomized controlled trials, focusing on first-line treatments for metastatic cancers, where ICIs plus CT are compared against CT. The meta-analysis reveals that the combination therapy significantly improves OS in certain cancer types like lung cancers (HR=0.79, 95%CI 0.73-0.86; P<0.01), esophageal (HR=0.68, 95%CI 0.6-0.77; P<0.01) and gastric carcinomas (HR=0,8, 95%CI 0.63-0.88; P<0.01). In other cancers, evidence is less strong (e.g, gynecological, breast, genitourinary, head and neck, and skin cancers).</p><p><strong>Conclusions: </strong>These findings suggest that while the addition of ICIs can enhance survival outcomes in a subset of elderly cancer patients, its efficacy is highly contingent upon the cancer type and the specific patient's health profile.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251328539"},"PeriodicalIF":2.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological characteristics and prognosis of cervical adenocarcinoma across diverse histological subtypes.","authors":"Xiaowan Guo, Miao Wang, Sisi Yan, Kehua Hu, Jiaqiang Xiong, Hui Qiu, Qiuji Wu","doi":"10.1177/03008916251341993","DOIUrl":"https://doi.org/10.1177/03008916251341993","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical features and prognostic implications of different subtypes of cervical adenocarcinoma.</p><p><strong>Methods: </strong>We examined 13,353 adenocarcinoma (AC) cases from the SEER database to identify distinct clinical characteristics and prognostic factors among various histological subtypes. Using the WHO classification and International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes, we categorized patients and assessed overall survival (OS) and cancer-specific survival (CSS) via Kaplan-Meier and Cox regression analyses. A nomogram was constructed to predict patient survival across subtypes.</p><p><strong>Results: </strong>Patients with non-usual type show a significantly poorer prognosis. Our analysis revealed that serous carcinoma patients had the most adverse outcomes (OS: hazard ratio (HR) = 2.69, 95% confidence interval (CI): 2.23-3.23, P < 0.001; CSS: HR = 1.78, 95% CI: 1.34-2.36, P < 0.001), while villous adenocarcinoma patients had the most favorable (OS: HR = 0.43, 95% CI: 0.29-0.65, P < 0.001; CSS: HR = 0.32, 95% CI: 0.17-0.60, P < 0.001), compared to the usual type. Multivariable Cox regression identified age, marital status, race, tumor grade, FIGO stage, and treatment as independent prognostic factors. In patients with serous carcinoma, advanced FIGO stage was a risk factor (stage IV vs stage I: HR = 4.06, 95% CI: 1.35-12.22, P = 0.013), and surgery was a protective factor (HR = 0.22, 95% CI: 0.10-0.49, P < 0.001). We also created a prognostic model incorporating diverse histological subtypes, internally validated for high predictive accuracy and discrimination via the receiver operating characteristic (ROC) curve and calibration plots.</p><p><strong>Conclusion: </strong>Clinical characteristics and prognostic features in cervical adenocarcinoma vary significantly by histological subtype, with serous carcinoma being associated with the worst outcomes.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251341993"},"PeriodicalIF":2.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ongoing discussion: Is prophylactic central neck dissection necessary in _cT_1a-b,2N₀ papillary thyroid cancer?","authors":"Ömer Bayır, Latif Akan, Muhammed Kızılgül, Bekir Uçan, Sevilay Karahan, Gökhan Toptaş, Şevket Aksoy, Esra Nur Bayır, Muhammed Erkam Sencar, Erman Çakal, Güleser Saylam, Mehmet Hakan Korkmaz","doi":"10.1177/03008916251334884","DOIUrl":"https://doi.org/10.1177/03008916251334884","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the central lymph node metastasis (CLNM) rates of patients who underwent prophylactic central lymph node dissection (pCLND) with total thyroidectomy for cT1-2N0 papillary thyroid cancer in our clinic, to evaluate the conditions associated with lymph node metastasis, and to examine the necessity of pCLND in these patient groups.</p><p><strong>Methods: </strong>This study includes a retrospective review of the medical data of patients who underwent bilateral/unilateral central lymph node dissection (CLND) (b/uCLND) with total thyroidectomy in our center between 2013 and 2021, whose fine needle aspiration biopsy result was reported as malignant, who were detected as cT1a-1b-2N0 on thyroid and neck ultrasonography.</p><p><strong>Results: </strong>Of the 251 patients included in the study, 63 (25%) had CLNM (49 (19.5%) ipsilateral and 14 (5.5%) had contralateral CLNM). Twenty-two (20.1%) of 109 patients with cT1a, 30 (28.3%) of 106 patients with cT1b, and 11 (30.5%) of 36 patients with cT2 had CLNM, and metastasis rates increased with increasing cT category. CLNM rates increased with increasing pT category (p=0.005). CLNM was present in 21 (38.8%) of 54 patients (21.5%) with collision tumors, and metastasis rates increased significantly compared to the presence of a single histopathologic tumor (p=0.006). CLNM rates were higher in patients with multicentric tumor localization than in those with unicentric localization (p=0.006).</p><p><strong>Conclusion: </strong>Multicentricity, bilaterality, capsule invasion, collision tumors and tumors larger than 1 cm increase the risk of CLNM. uCLND for tumors larger than 1 cm, bCLND for tumors larger than 2 cm can be considered. We believe that patients with unilateral CLNM also have an increased risk of contralateral metastasis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251334884"},"PeriodicalIF":2.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of Aurora B expression in cancer patients: A meta-analysis.","authors":"Md Mojahidur Hasan, Sehreen Tory, Yusuf Kemal Arslan, Yasemin Saygideger, Yusuf Tutar","doi":"10.1177/03008916251343384","DOIUrl":"10.1177/03008916251343384","url":null,"abstract":"<p><strong>Background: </strong>Overexpression of Aurora B is linked to poor prognosis in various malignancies; however, its prognostic role remains debatable. Conducting a meta-analysis is essential to reach a definitive conclusion.</p><p><strong>Methods: </strong>Various databases were searched. Aurora B protein expression was assessed for prognostic significance using pooled hazard ratio (HR) with a 95% confidence interval (CI). Meta-regression and subgroup analysis identified the source of heterogeneity.</p><p><strong>Results: </strong>The study comprised 1384 cancer patients from 10 articles. The result with multivariate data (pooled HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%) and univariate data (pooled HR=1.81, 95% CI=0.92, 3.57, p=0.09, I²=89%) showed that increased Aurora B expression was not linked with poor overall survival (OS). Subgroup analysis showed that sample size, follow-up time, cut-off value, non-Chinese patients, antibody source were not associated with unfavorable OS.</p><p><strong>Conclusions: </strong>Aurora B expression could not be used as a prognostic marker in cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"253-260"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humanistic nursing combined with Neuman's nursing in the application for oncology patients.","authors":"Jingjiao Wang, Meihong Wang, Jianhui Zhao","doi":"10.1177/03008916251338967","DOIUrl":"10.1177/03008916251338967","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to explore the application effects of humanistic nursing combined with Neuman's nursing in oncology patients.</p><p><strong>Methods: </strong>One hundred oncology patients were randomly divided into the observation and control groups, with 50 patients in each. Comparisons were made between both groups in terms of SF-36 scores, treatment compliance, nursing quality scores, Self-Rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) scores, and Pittsburgh Sleep Quality Index (PSQI) scores.</p><p><strong>Results: </strong>The observation group showed higher scores in the physical domain, physiological function, material life, and overall health of the SF-36 scale (<i>P</i> < 0.05). The observation group also exhibited higher treatment compliance rate (<i>X²</i> = 9.470), and higher scores in nurse-patient communication, nursing system, nursing service, and nursing environment of the nursing quality assessment (<i>P</i> < 0.05). After nursing, the observation group performed lower SAS and SDS scores (<i>t</i> = 17.556, 10.004), and higher scores in sleep quality, sleep duration, sleep disturbance, sleep onset latency, sleep efficiency, hypnotic medication use, and daytime dysfunction based on the PSQI (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The combination of humanistic nursing and Neuman's nursing improves the quality of life and treatment compliance in oncology patients, with improvements in negative emotions and sleep quality. However, this study's small sample of 100 cancer patients may not fully represent the diverse characteristics of various cancer types and stages, limiting conclusion generalizability. Furthermore, the short duration may have missed later-stage nursing intervention impacts. Thus, large-scale, long-term research is needed to provide reliable clinical evidence.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"229-237"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased expression of FGF14 and SCN2A/SCN11A is associated with better survival of HCC patients.","authors":"Walizeb Khan, Hifsa Younas, Ahmad Zeb, Muhammad Faraz Arshad Malik, Muhammad Saeed, Farhan Haq","doi":"10.1177/03008916251334565","DOIUrl":"10.1177/03008916251334565","url":null,"abstract":"<p><strong>Background: </strong>The clinical significance of fibroblast growth factor receptors (FGFRs) and their ligands in hepatocellular carcinoma (HCC) is extensively studied. Recently, regulation of voltage-gated sodium channels by FGFs in cancer has been reported.</p><p><strong>Materials and methods: </strong>We investigated the relationship between FGF family genes and voltage-gated sodium channel genes (SCN) using three independent microarray and RNA-seq cohorts HCC patients. <i>In vitro</i> validation of 100 tissues of HCC patients with 50 control samples was performed. Statistical validation included the Wilcoxon test, Mann-Whitney U-test, correlation, Kaplan-Meier survival, and univariate and multivariate Cox regression survival analyses.</p><p><strong>Result: </strong>The initial analysis of intracrine FGF (iFGF) ligands showed dysregulation of iFGF genes in HCC with strong association with each other in all datasets. According to <i>in vitro</i> analysis, overexpression of <i>FGF14</i> was also observed in HCC patients suggesting potential role of <i>FGF14</i> in HCC.Furthermore, network analysis showed that <i>FGF14</i> was strongly interacting with SCN genes. Interestingly, SCN genes were also found in HCC samples with a positive correlation with <i>FGF14</i> expression. The clinical analysis showed that <i>FGF14</i>, <i>SCN2A</i> and <i>SCN11A</i> are significantly associated with better disease-free survival, whereas multivariate regression analysis showed <i>SCN11A</i> as an independent predictor of disease-free survival in HCC patients.</p><p><strong>Conclusion: </strong>The dysregulation of <i>FGF14</i> and SCN family genes suggests a new molecular mechanism in the regulation of HCC. Furthermore, <i>SCN11A</i> was identified as a possible predictor for disease-free survival in HCC. Investigating these gene families using clinical studies may lead to new therapeutic approaches for HCC treatment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"238-245"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET/CT guided salvage radiotherapy strategies for lymph-nodal relapses in gynecological cancers: SBRT vs ENRT.","authors":"Andrei Fodor, Martina Midulla, Chiara Brombin, Paola M V Rancoita, Alice Bergamini, Paola Mangili, Miriam Torrisi, Lucia Perna, Emanuela Rabaiotti, Italo Dell'Oca, Chiara L Deantoni, Luca Bocciolone, Claudio Fiorino, Antonella Del Vecchio, Mariaclelia S Di Serio, Giorgia Mangili, Nadia G Di Muzio","doi":"10.1177/03008916251336055","DOIUrl":"10.1177/03008916251336055","url":null,"abstract":"<p><strong>Objective: </strong>To identify outcome differences between extended nodal radiotherapy (ENRT) with simultaneous integrated boost (SIB) and stereotactic body radiotherapy (SBRT), performed with advanced radiotherapy techniques, both of which were 18F-Fluoro-Deoxy-Glucose (FDG) PET/CT guided, for lymph-node (LN) relapses of gynecological tumors, and to identify the most important determining factors.</p><p><strong>Methods: </strong>Records of gynecologic patients treated in a single-institution with FDG PET/CT guided intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), or SBRT, were reviewed, and only patients at first salvage radiotherapy for LN relapses were considered. Local relapse-free- (LRFS), regional relapse-free- (RRFS), distant metastasis-free- (DMFS), disease-free-(DFS) and overall-survival (OS), as well as acute and late toxicity (with CTCAE v5.0 score), were determined.</p><p><strong>Results: </strong>Fifty-eight patients (23 ENRT+SIB; 35 SBRT) treated for 178 LNs from February 2007-April 2023, were identified. Median biological equivalent dose (BED10) delivered to PET-positive LNs was 76.5 Gy (Interquartile range-IQR- 74.4;78.7) for ENRT, and 72 Gy (IQR 59.5;75.6) for SBRT. Median follow-up was 81.1(IQR 48.5; 117.2) and 37.0 (IQR 21.3; 58.4) months for ENRT and SBRT, respectively. Thirty-six-month estimated LRFS was 90.2% for ENRT and 82.6% for SBRT; RRFS was 69% and 63.4%, DMFS 26.1% and 44.3%, and OS 73.7% and 60.4%; no statistically significant differences were found between the two groups (logrank test, p= 0.29). ENRT recorded more acute (p⩽0.033), but not late, toxicities.</p><p><strong>Conclusions: </strong>ENRT+SIB and SBRT for gynecological LN tumor relapses obtain similar results in terms of disease-free and OS, with fair toxicity. Prospective studies with higher patient numbers are needed.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"219-228"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of the new European CTR on academic clinical research: A survey by the Italian Sarcoma Group Federated Trial Centre.","authors":"Viviana Appolloni, Gianluca Ignazzi, Daniela Salvatore, Simone De Meo, Salvatore Vizzaccaro, Silvia Stacchiotti, Giacomo Giulio Baldi, Celeste Cagnazzo","doi":"10.1177/03008916251330093","DOIUrl":"10.1177/03008916251330093","url":null,"abstract":"<p><strong>Objective: </strong>The Clinical Trials Regulation EU 536/2014 (CTR) has presented challenges for adapting experimental centres. To address this regulatory change, in 2023, the Italian Sarcoma Group (ISG) established a Federated Trial Centre (FTC) model, including Clinical Research Coordinators (CRCs) and Research Nurses (RNs).</p><p><strong>Methods: </strong>To explore the CTR's impact, a 40-question survey was launched in April 2023, distributed among 48 FTC members from 27 Italian institutions, with 30 responding.</p><p><strong>Results: </strong>46.6% of responders reported the progress of their institutions in adapting to the regulation, 70% had good knowledge of the updates, 60% confirmed staff training on the CTIS (Clinical Trials Information System). However, 63.3% noted that administrative personnel were not aligned with new contract deadlines, and only in 26.6% of cases institutions offered CTR-specific training. Additionally, 53.4% expressed concerns that the CTR does not support academic research.</p><p><strong>Conclusion: </strong>The ISG's FTC model was assessed as promoting collaboration between clinicians, staff, and CRCs to improve the management of academic studies and raise awareness within the sarcoma research community, by defining roles for CRCs and RNs and proposing collaborative projects and meetings.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"246-252"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}